What is the typical dosage and treatment duration for Bactrim (trimethoprim/sulfamethoxazole)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bactrim (Trimethoprim-Sulfamethoxazole) Dosing and Duration

For acute uncomplicated cystitis in women, use Bactrim 160/800 mg (one double-strength tablet) twice daily for 3 days, but only if local resistance rates are below 20% and the pathogen is known to be susceptible. 1

Acute Uncomplicated Cystitis

Standard Dosing

  • 160/800 mg (one double-strength tablet) twice daily for 3 days is the evidence-based regimen 1
  • Clinical cure rates of 85-100% and bacterial cure rates of 85-100% have been demonstrated with 3-day therapy 1

Critical Resistance Considerations

  • Bactrim is no longer recommended as first-line empiric therapy due to rising resistance rates globally 1
  • Use only when local E. coli resistance is documented to be <20% 1
  • If susceptibility is unknown, choose an alternative agent (nitrofurantoin or fosfomycin) 1
  • When resistance is present, clinical cure drops dramatically from 84% to 41% 1

Alternative Duration

  • 7-day regimens (160/800 mg twice daily) show similar efficacy to 3-day courses but with significantly higher adverse event rates (38% vs 31%) 1

Acute Uncomplicated Pyelonephritis

Standard Dosing

  • 160/800 mg (one double-strength tablet) twice daily for 14 days when the pathogen is known to be susceptible 1
  • Requires an initial IV dose of ceftriaxone 1g or consolidated aminoglycoside if susceptibility is unknown at treatment initiation 1

Key Restrictions

  • Never use empirically without knowing susceptibility 1
  • Fluoroquinolones are preferred for empiric therapy when local resistance is <10% 1

Pneumocystis jirovecii Pneumonia (PCP)

Treatment Dosing

  • 75-100 mg/kg/day sulfamethoxazole with 15-20 mg/kg/day trimethoprim divided every 6 hours for 14-21 days 2
  • For a 70 kg adult: 4 teaspoonfuls (20 mL) every 6 hours 2

Prophylaxis Dosing

  • Adults: 160/800 mg (one double-strength tablet) once daily 1, 2
  • Children: 150 mg/m²/day trimethoprim with 750 mg/m²/day sulfamethoxazole divided twice daily, given 3 consecutive days per week 3, 2
  • Alternative pediatric dosing: 8 mg/kg/day of trimethoprim component divided twice daily 3

Other Indications

Shigellosis

  • Adults: 160/800 mg twice daily for 5 days 2
  • Children: 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours divided every 12 hours for 5 days 2

Acute Otitis Media (Children)

  • 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours divided every 12 hours for 10 days 2

Chronic Bronchitis Exacerbations

  • 160/800 mg twice daily for 14 days 2

Traveler's Diarrhea

  • 160/800 mg twice daily for 5 days 2

Renal Dosing Adjustments

  • CrCl >30 mL/min: Standard dosing 2
  • CrCl 15-30 mL/min: Reduce dose by 50% 2
  • CrCl <15 mL/min: Not recommended 2

Critical Monitoring Requirements

For Prophylactic Use

  • Complete blood counts with differential and platelet count at initiation and monthly thereafter to detect hematologic toxicity 3
  • Approximately 2% of patients develop severe anemia by 18 months when used long-term 1

Common Pitfalls

  • Do not use for empiric UTI treatment without knowing local resistance patterns - resistance correlates directly with treatment failure 1
  • Do not use amoxicillin or ampicillin instead - these have very high resistance rates worldwide and poor efficacy 1
  • Avoid 10-day courses for simple cystitis - 3-day therapy is equally effective with fewer side effects 1
  • Never use for pyelonephritis without susceptibility data or initial IV therapy - this is a critical safety issue 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Prophylaxis with Septran DS in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.